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KU-32 is a novel, novobiocin-based Hsp90 inhibitor that protects against neuronal glucotoxicity and reverses multiple clinical
indices of diabetic peripheral neuropathy in a rodent model. However, any drug with potential for treating diabetic complications
must also have no adverse effects on the function of pancreatic islets. Thus, the goal of the current study was to assess the effect
of KU-32 on the in vitro viability and function of human islets. Treating human islets with KU-32 for 24 hours showed no
toxicity as assessed using the alamarBlue assay. Confocal microscopy confirmed that with a minimum of 2-day exposure, KU-
32 improved cellular viability by blocking apoptosis. Functionally, isolated human islets released more glucose-stimulated insulin
when preincubated in KU-32. However, diabetic BKS-db/db mice, a model for type 2 diabetes, administered KU-32 for 10 weeks
did not show any significant changes in blood glucose and insulin levels, despite having greater insulin staining/beta cell in the
pancreas compared to untreated BKS db/db mice. In summary, KU-32 did not harm isolated human islets and may even be
protective. However, the effect does not appear significant enough to alter the in vivo metabolic parameters of diabetic mice.
1. Introduction
Both type 1 and type 2 diabetes encompass elements of
islet destruction, although by different mechanisms. Islet
health is essential to maintaining normal glucose levels, and
numerous approaches are being taken in attempts to prolong
the life of the islet β cells. Previous studies have indicated
that chaperone proteins, specifically heat shock protein 70
(Hsp70), can attenuate the cellular stress associated with type
2 diabetes and the eventual loss of islets [1].
KU-32 is a novel novobiocin-based Hsp90 inhibitor that
can protect against neuronal cell death in vitro with minimal
cytotoxicity to neurons [2, 3]. KU-32 protected against
sensory neuron death and demyelination, and reversed
the sensory deficits associated with diabetic peripheral
neuropathy [4]. Mechanistically, the neuroprotective actions
of KU-32 required the presence of a second molecular
chaperone, Hsp70, because KU-32 was unable to reverse
diabetic peripheral neuropathies in Hsp70.1 and Hsp70.3
double knockout mice [4].
Hsp70 has been identified within the insulin and amylin
granules of pancreatic β-cells [5, 6], and its levels increased
following exposure to interleukin-1β in cultured islets [7].
Overexpression of Hsp70 attenuated ER stress in cultured
islets [8], and cellular death induced by NO donor com-
pounds [7]. Conversely, while overexpression of Hsp70 has
been associated with enhanced resistance to inflammatory
mediators [9], actual heat exposure to isolated islets induced
cellular apoptosis. Thus, activation of a cadre of heat shock
proteins, including Hsp70, can cause apoptosis, resulting in
increased graft failure after islet transplantation [10]. In fact,
in pig islets, preconditioning with heat to activate Hsp70
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Table 1: Characteristics of human islet donors.
Sex Age (years) BMI Race Cause of death
F 44 22.5 White Head trauma
M 30 27.6 White Head trauma
M 30 26.2 White Cerebrovascular stroke
M 44 30.4 White Head trauma
F 55 26.8 AA Head trauma
F 47 26.3 White Cerebrovascular stroke
F 58 25.8 Unknown Unknown
F 38 30 AA Unknown
M 54 32 White Gunshot
F 26 33 AA Head trauma
M 44 26.3 White Head trauma
M 49 34.5 Unknown Unknown
M 27 33 White Head trauma
BMI: body mass index; M; male; F: female; AA: African American.
protected the islet grafts from early inflammation after islet
transplant, but enhanced eventual rejection of the islets by
the recipient [11].
Recent data suggest that KU-32 may improve neuronal
function by enhancing mitochondrial respiratory capacity
following hyperglycemic stress [12, 13]. Since emerging
research indicates that diabetes (especially type 2 diabetes)
increases oxidative stress and mitochondrial fission/fusion
in sensory neurons [14], the actions of KU-32 are enticing
as a possible novel pharmacological intervention to reverse
diabetic peripheral neuropathy. Given the complexity of
Hsp70 on islet function and the critical role of this protein
in KU-32-mediated neuroprotection, it is important to
measure the effect of KU-32 on islet health and function
since any therapeutic used to manage diabetic complications
should, at the least, have a neutral if not beneficial effect on
islets.
2. Materials and Methods
2.1. Human Islet Procurement. Human tissues were obtained
from the Integrated Islet Distribution Program (IIDP)
and BetaPro (Gordonsville, VA). The samples of isolated
islets were from 13 adult donors, whose characteristics are
described in Table 1. None of the donors were diagnosed
with diabetes or metabolic syndrome. Females comprised
46% of the sample donors, and the average age was 42
years. The majority of the donors were white with 23%
African American, and no other donor minority status
was identified. The average body mass index (BMI) was
29.55. Most donors died of head trauma (54%), 2 died of
cerebral vascular strokes, and one of a gunshot wound. Three
donors’ cause of death was unknown. Isolated islets from the
donors were maintained in CMRL 1066 medium with 2 mM
glutamine, 10% FBS, and 1% antibiotic/antimycotic at 37◦C
in a culture chamber containing 5% CO2.
2.2. Animals. Male and female lepr mice (strain name:
BKS.Cg-Dock7 m +/+ Lepr db /J) were purchased from
Jackson Laboratory (Bar Harbor, ME, USA) and a breeding
colony was established to generate animals with the
homozygous genotype. Animals were housed 2 to 5 mice
per cage and were kept on a 12 : 12-hour light/dark cycle
with free access to food (5001 Purina Laboratory Rodent
Diet, Purina Mills, St. Louis, MO, USA) and water. Weekly
fasting blood glucose levels (One-Touch Ultra glucometer)
were assessed and compared to age-matched heterozygous,
nondiabetic litter mates. At 10 weeks of age, animals
were given once per week intraperitoneal injection of 5%
Captisol (CyDex Pharmaceuticals, Lenexa, KS, USA) or
20 mg/kg KU-32 in 5% Captisol. At termination of the study,
blood from each animal was collected into 1.5 mL tubes
containing 300 mM of EDTA, which was then centrifuged
at 1500×g for 10 minutes at 4◦C. The supernatant was
collected and serum insulin levels were determined by
ELISA (ALPCO, Salem, NH, USA, no. 80-INSMSU-E01).
KU-32, [N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-
6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-
oxo-2H-chromen-3-yl)acetamide], was synthesized and
structural purity (>95%) verified as described in [15].
All animal procedures were performed in accordance
with protocols approved by the University of Kansas Animal
Care and Use Committee which is in compliance with
National Institute of Health guidelines.
2.3. Toxicity Assays. Possible toxicology of KU-32 was deter-
mined using alamarBlue (Invitrogen). Islets were placed
into 96-well plates and subjected to a 8-point dose of KU-
32 in either low (5 mM) or high (17.5 mM) glucose in
DMEM : F12 media and incubated overnight at 37◦C and
5% CO2. Twenty-four hours later, alamarBlue was added
directly to each well to achieve a final concentration of
10% alamarBlue. Readings on a microplate reader (excitation
wavelength = 530 nm and emission = 590 nm) were collected
4, 24, and 48 hours later. Blank wells containing media
were used to determine background fluorescence. Data
were calculated as Normalized Relative Fluorescence Units
(NRFU/IE) according to manufacturer’s instructions.
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Figure 1: KU-32 improved viability of isolated human islets. (a) Toxicity studies using alamarBlue as an indicator of cell number shows no
statistically significant toxic effect of KU-32 on human islets after a 24-hour exposure to 7 half-log doses (n = 6 replicates). (b) Representative
islets are shown from vehicle-exposed islets (left) and KU-32- (1 μM) treated islets. Viability was determined using fluorophores that indicate
apoptosis (green staining) and necrosis (red staining). Scale bars = 100 μm. (c) The percentage of cells within islets that were dead (stained
red or green) were calculated as islets exposed to KU-32 or vehicle were maintained in cultures. (∗indicates P < 0.001, n = 201 vehicle-
treated and 177 KU-32-treated islets). (d) Further analysis of the percentage of cell death due to apoptosis or necrosis indicates that the
majority of cell death was due to apoptosis in the vehicle islets while there was no difference in the low levels of apoptosis or necrosis in the
KU-32-treated islets. (∗indicates P < 0.001 between KU-32 and vehicle groups, n = 49 vehicle-treated and 59 KU-32-treated islets).
2.4. Viability Assay. Islets were placed in a 500 mL volume
of L-15 medium with live/dead fluorophores. The standard
assay for cell apoptosis and necrosis included assessment
of DNA fragmentation and loss of membrane integrity
by exposing islets to YO-PRO-1 and propidium iodide
(Vybrant Apoptosis Assay, Invitrogen, Grand Island, NY,
USA, no. V13243) for 30 min at 37◦C. Islets were rinsed
with PBS and imaged with an Olympus Fluo laser scanning
confocal microscope with a 20 or 40X objective. Background
fluorescence was subtracted and viability percentages were
calculated using FluoView software. The ratio representing
the live cell area divided by the total islet area was calculated
and reported as the percentage of dead cells. Islets were
stressed, as indicated in the results section, by cycling high
CO2 levels. Control and KU-32 treated islets were placed in
stress media (DMEM with 1% FBS and 5.5 mM glucose). The
islets were cycled between 5% CO2 and 20% CO2 for 2 hours
at 37◦C.
2.5. Cellular Oxygen Consumption. Cellular oxygen con-
sumption was completed using our published protocol
[16]. Islets were exposed to 1 μM KU-32 or vehicle for 24




































Figure 2: KU-32 increased oxygen consumption per islet. Exposure
to KU-32 increased oxygen consumption per islet through an 18-
hour period. Measurements were made in triplicate wells with 13–
33 islet equivalents (IE)/well.
hours in 96-well plates. The islets were transferred into
oxygen-sensing, 96-well microplates (BD Biosciences), in
Ham’s media. Fluorescence of the individual wells, indicating
relative changes in O2 consumption, was measured on a UV
microplate reader (excitation wavelength of 485 nm, emis-
sion at 590–630 nm). The plate was read repeatedly over an
18-hour period. The values were normalized by subtracting
the average of three blank wells from each measured well.
Finally, values were divided by islet equivalencies to yield the
O2 consumption/islet equivalency.
2.6. Protein Extraction and Western Blot. After washing,
the islets were homogenized and protein extracted. Mea-
surement of protein concentrations in supernatants was
performed using BCA Protein Assay Kit (Pierce, Rockford,
IL, USA, no. 23225). Proteins were separated on a 4–15%
Tris-HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA,
USA, no. 161-1158) with 0.025 M Tris, 0.192 M Glycine,
0.1% SDS running buffer. Equal amounts of total protein
(20 μg) were loaded in each lane. After electrophoresis,
the proteins were transferred from the gel to Bio Trace
PVDF membranes 0.45 μm (Pall Life Sciences, East Hills, NY,
USA, no. P/N 66547), and visualized after staining in 0.1%
Ponceau’s solution, 5% acetic acid to ensure completeness of
the transfer. Blots were blocked with 5% nonfat dry milk.
Blots were probed with primary antibody against Hsp70
(ENZO Life Sciences, Plymouth Meeting, PA, USA, no. ADI-
SPA-810) for 1 hour, dilution 1 : 1,000 followed by washing
and exposure to secondary antibody horseradish peroxidase-
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA, no. sc-2005), dilution 1 : 2,000.
After repeated washings bound antibodies were detected
using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific Inc., Rockford, IL, USA, no. 34080). In
order to normalize the protein loading by a housekeep-
ing protein, the membranes were stripped, reprobed with
antibody against actin (Sigma, Saint Louis, MO, USA, no.
A2066, dilution 1 : 5,000) and processed with corresponding
secondary antibody and the chemiluminescent substrate.
Intensity of protein bands was quantified using Adobe Pho-
toshop software. Protein loading was normalized by dividing
intensity values for Hsp70-specific bands by intensity values
for actin-specific bands.
2.7. Insulin Secretion. Static insulin secretion was measured
from isolated human islets, placed in duplicate wells and
assigned to two groups: low glucose (3 mM) and high glucose
(16 mM) using our published protocol [17]. Briefly, islets in
each well were exposed to KU-32 for varying times from
30 minutes to 24 hours. The media were changed and islets
were exposed for 30 minutes in RPMI 1640 containing 3 mM
glucose maintained at 37◦C with 5% CO2. Low or high
glucose solutions were added to the respective duplicates.
After 30 minutes of static incubation at 37◦C and 5% CO2,
the islets were sedimented and the conditioned medium was
collected and frozen at −80◦C to determine insulin content
by ELISA (ALPCO, Salem, NH, USA, no. 80-INSHU-E10.1).
Perifusion insulin secretion experiments were completed
based on our published procedures [18]. Islets were incu-
bated in CMRL 1066 overnight in a 37◦C culture chamber
containing 5% CO2 overnight, exposed to 1 μM KU-32.
Media were changed for a 2-hour preincubation. The islets
were incubated in 5 mM RPMI 1640 with 10% FBS in
37◦C incubator with 5% CO2 and placed in our custom
perifusion chamber with a volume of 700 μL, maintained at
37◦C. Islets were initially perfused with 3 mM glucose RPMI
1640 with 10% FBS and 17 mM mannitol at a flow rate of
250 μL per min for 30 minutes prior to sample collection.
Samples were taken at 10-minute intervals for 60 minutes
in low glucose. The glucose concentration was increased
to 20 mM for 60 min, followed by a return to the 3 mM
glucose concentration for 60 minutes. Collected fractions
were flash frozen and stored at −80◦C for determining
insulin concentrations using a sandwich ELISA procedure
(ALPCO, Salem, NH, USA, no. 80-INSHU-E01.1).
2.8. Pancreatic Sections. The pancreata from mice were
rapidly harvested and fixed in 10% normal buffered for-
malin. The tissues were subsequently dehydrated in graded
concentrations of ethanol, cleared in xylene, and subse-
quently embedded in paraffin wax at 55◦C. The tissues were
sectioned at 8 μm thickness, mounted on Superfrost/Plus
microscope slides (Fisher Scientific, Pittsburg, PA, USA,
no. 12-550-15) and dried at 40◦C overnight and stored at
4◦C until processing. The paraffin-embedded sections were
deparaffinized/rehydrated in xylene followed by ethanol and
PBS serial rehydration. Antigen retrieval was completed in
0.01 M citrate buffer, pH 6.2, with 0.002 M EDTA for 30 min
using a steamer. Cells were permeabilized in 1.0% Triton X-
100 in 0.1 M PBS, pH 7.4 for 30 min. Hematoxylin and eosin
(H&E) staining was performed to illustrate the general islet
morphology under light microscopy.
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Figure 3: KU-32 increased insulin secretion. (a) In perifusion experiments, exposure to KU-32 increased insulin secretion in response to
high-glucose. Initially, islets were maintained in 3 mM glucose. At time 0, the perfusate was switched to 17.3 mM glucose (high-glucose
conditions). After 30 minutes, the glucose level was returned to 3 mM. During the high-glucose stimulation, there was significantly more
insulin released by the KU-32-treated islets compared to the vehicle-treated. During low-glucose exposure, there was no difference between
the 2 groups. (∗indicates P < 0.05, n = 3 separate trials). (b) Insulin secretion measured during static incubation resulted in similar findings
with statistically more insulin released in high glucose from the KU-32-treated islets. (∗indicates P < 0.01).
2.9. Immunofluorescence Staining. Sections were blocked in
10% normal donkey serum, 1.0% bovine serum albumin
(BSA), and 0.03% Triton X-100 diluted in 0.1 M PBS, pH
7.4 for 30 min. Incubation with the primary antibody mix
was performed at 4◦C overnight in a wet chamber followed
by incubation with the mix of fluorophore-conjugated
secondary antibody at room temperature for 2 hr in a wet
chamber protected from light. Both primary and secondary
antibodies were diluted in 1% NDS, 1% BSA, and 0.03%
Triton X-100. Slides were mounted with antifading agent
Gel/Mount (Biomeda, Foster City, CA, USA, no. M01). The
following primary antibodies were used: anti-insulin (1 : 100,
Abcam, Cambridge, MA, USA, no. ab7842), antiglucagon
(1 : 200, Abcam, no. ab10988), and antisomatostatin (1 : 200,
Abcam, no. ab53165). Corresponding secondary antibodies
were conjugated with Cy2 (1 : 200, Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA, no. 706-225-148),
Alexa 555 (1 : 400, Molecular Probes, Eugene, OR, USA,
no. A31570), and Alexa 647 (1 : 400, Molecular Probes, no.
A31573). Images were collected using a Nikon C1si confocal
microscope.
2.10. Statistics. For insulin secretion assays, two-way
ANOVA with Fisher’s least significant difference test was
used to compare groups. A t-test was used to compare total
insulin content. Oxygen consumption data were analyzed
using repeated measures ANOVA. For the immunostaining
experiments, nested ANOVA was used. All figures include
means ± SE. P value, defined as <0.05, was considered
statistically significant.
3. Results
Isolated islets are extremely fragile in vitro due to cell
death from both apoptosis and necrosis [16, 17]. If KU-32
were to be used as a clinical intervention for patients with
diabetic peripheral neuropathy, any possible cytotoxicity
to islets must be avoided. Initial cytotoxicity studies were
performed in 5 mM glucose with doses of KU-32 from 0.03
to 30 μM. After 24 hours of exposure to KU-32, there was no
measureable cell loss to the islets exposed to any of the doses
tested (Figure 1(a)). Replicate studies in high glucose also
showed no signs of toxicity (results not shown). These initial
toxicology screens, using the alamarBlue assay, provided
general information concerning changes in cell numbers, but
the natural heterogeneity in the size of native islets (ranging
from 50–400 μm diameters), along with the natural donor-
to-donor variability, resulted in large variations, as noted by
the error bars in Figure 1(a). Thus, we conducted additional
viability studies using apoptosis/necrosis fluorophores and
confocal microscopy.
Figure 1(b) (left) provides a typical example of cell death
associated with the vehicle-treated islets. The green staining
indicates cell death due to apoptosis, and red is associated
with necrotic cell death. In contrast, islets exposed to KU-32
showed less cell death (Figure 1(b), right). Islets maintained
in culture have an increasing percentage of cell death, as
we and others have shown [16, 17, 19, 20]. Exposure to
KU-32 halted the time-dependent increase in cell death.
Figure 1(c) illustrates the progressive loss of viable cells/islets
in the control group, while continued exposure to 1 μM
KU-32 for the duration of the experiment maintained cell
death at around 10% in the treated group. Shorter time
6 Experimental Diabetes Research



























Figure 4: KU-32 failed to induce an increase in Hsp70 levels. (a)
A typical western blot is shown with Hsp70 from samples of islets
treated with vehicle (V) or KU-32 (T). MW size indicated on left.
(b) Densitometry measurements of repeated western blots indicate
that there was no difference in Hsp70 levels between vehicle- and
KU-32 treated islet samples. When islets were stressed, Hsp70 levels
increase and KU-32 exposure brought them back towards baseline,
but these differences were not significant (n = 2 separate trials).
points were also tested starting with a 1-hour exposure.
However, exposure durations of less than 48 hours failed
to significantly alter cell viability. Of interest, the majority
of cells died due to apoptosis. Figure 1(d) shows that far
fewer apoptotic cells were found in islets exposed to KU-
32 compared to the controls. In contrast the amount of
cell death due to necrosis was identical in both groups, but
relatively low.
Further confirmation that KU-32 protected cells from
apoptosis came from oxygen consumption studies. At each
time point tested, oxygen consumption was greater per islet
when exposed to KU-32 (Figure 2). Although the oxygen
consumption per islet was increased with KU-32, when the
oxygen consumption data were normalized to the percentage
of viable cells within each islet (using the data shown in
Figure 1), group differences in oxygen consumption were
ablated (data not shown). In summary, the increased oxygen
consumption associated with the KU-32 exposed islets was
likely due to the increased number of live cells rather than
changes in the cellular respiration.
To determine whether KU-32 altered function in β cells,
perifusion experiments were performed on human islets.
Islets were first exposed to low glucose (3 mM) for 90
minutes. Subsequently, the perfusate was switched to high
glucose (20 mM) and the supernatant collected. While there
was no significant effect by KU-32 on the insulin secreted in
low-glucose conditions, there was significantly more insulin
released in response to high glucose from the islets preex-
posed to KU-32 (Figure 3(a)). Repeated static incubation
studies showed similar results with statistically higher insulin
release in the KU-32 exposed islets (Figure 3(b)). In low
glucose (3 mM), there was no effect of KU-32 on insulin
secretion. The improved insulin secretion was demonstrated
with a minimum of 16 hours of exposure prior to the
assay. One-hour exposures to KU-32 failed to stimulate
an improvement in insulin secretion even in high-glucose
conditions (data not shown).
The molecular mechanism responsible for the neuro-
protective effects of KU-32 depends on inhibition of Hsp90
and subsequent expression of Hsp70 [4]. Thus, we measured
Hsp70 levels in human islets exposed to KU-32 for 24 hours.
Figure 4(a) presents a typical western blot recognizing Hsp70
and the housekeeping protein, actin. Surprisingly, there was
no difference in Hsp70 levels between the vehicle- (V) and
KU-32-treated (T) islets when normalized to actin levels
(Figure 4(b)). Isolated islets normally express a high level
of Hsp70; therefore, KU-32 may not have had an effect
on quiescent islets. We stressed the islets by incubating
them in hypoxic conditions with acidic media while exposed
to either vehicle or KU-32. Control and KU-32 treated
islets were placed in stress media (see methods) and cycled
between 5 and 20% CO2. Under these conditions, islets
had more Hsp70 in the stressed conditions (although not
statistically different from basal conditions), but instead of
KU-32 increasing the Hsp70 levels further, it returned Hsp70
back toward baseline levels (Figure 4(b)).
In order to determine whether the protective action
of KU-32 on islets existed in vivo, diabetic Lepr db mice
were treated with weekly injections of KU-32. Elevations in
blood glucose levels in these mice generally occur at ages 4
to 8 weeks of age. Therefore, once chronic hyperglycemia
was confirmed, weekly KU-32 injections were administered
starting at 10 weeks of age and continuing for 8 weeks.
Blood glucose levels were not different between the vehicle
and KU-32-treated animals (Figure 5(a)). Likewise, there
was no difference in the serum insulin levels in the KU-32
versus vehicle-treated animals at the termination of the study
(Figure 5(b)). Likewise, there were no signs of toxicity in the
KU-32-treated animals.
At the termination of the study, the pancreata were
removed and analyzed using immunofluorescence. Islet
morphology was clearly different in the diabetic mice.
Islets were either intact, or they had large areas devoid
of α, β, or δ cells, termed disrupted islets [21]. Finally,
there was a third category of islets that was composed of
scattered endocrine cells, defining an area that had once been
an islet. These morphological categories could be viewed
with both immunofluorescence and immunohistochemistry
techniques (Figure 6(a)). Both vehicle- and KU-32-treated
animals had islets that fell into the three categories and there
was no difference in the distribution of islets within each
category between groups (Figure 6(b)).
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Figure 5: KU-32 did not alter blood glucose and insulin levels in vivo. (a) Weekly blood glucose measurements demonstrate that both
groups of animals were diabetic, and levels were not affected by KU-32 administration (n = 12 vehicle- and 16 KU-32-treated mice). (b)
At the termination of the study serum insulin levels were not different between the vehicle- and KU-32-treated mice (n = 3 vehicle- and 4
KU-32-treated mice).
From the serial sections, islet area was measured, and
there was a statistically significant increase in total area
of the endocrine-stained cells in the KU-32-treated mice
(Figure 7(a)). In summary, more total pancreatic area was
composed of α, β, or δ cells with KU-32 treatment. However,
the density of islets per microscopic field in the pancreas tail
decreased in the KU-32-treated animals (Figure 7(b)).
We hypothesized that KU-32 would spare some of the
diabetes-induced loss of endocrine cells within the islets,
by sparing the β-cells specifically. Thus, we compared the
percentage of α, β, and δ cells within the islets. These
measurements were only made on intact and disrupted islets
(not scattered cells). Figure 7(c) shows that there was no
difference between the two groups, with both groups of islets
showing a dominant percentage of β-cells (Figure 7(c)).
While there was no difference in the percentage of β-cell
to other endocrine cells with KU-32 administration, there
was a clear difference in the intensity of the insulin staining,
which is indicative of the insulin level/cell. Insulin staining
intensity was greatest in the KU-32-treated animals when
calculated per islet (Figure 8(a)) and per β-cell (Figure 8(b)).
4. Discussion
Approximately 26 million Americans are diagnosed with
diabetes and approximately 60–70% of those individuals
develop diabetic peripheral neuropathies. To date, there are
no effective treatment options specific to the neuropathy.
KU-32 is a small molecule designed to inhibit Hsp90,
thereby increasing Hsp70 levels. Both Hsp70 and Hsp90
are molecular chaperones that are critical for the proper
folding of proteins. KU-32 has been shown to have dramatic
effects in protecting neurons from stress and even reversing
the clinical signs of diabetic neuropathy in animal models.
Treatment of diabetic rodents reversed multiple clinical indi-
cators of diabetic peripheral neuropathy including thermal
hypoalgesia [4] and mechanical sensitivity [12]. If it is to be
administered as an antineuropathy drug to diabetic patients,
any possible effects on islets must first be identified.
In this study, we showed that KU-32 improved human
islet cell viability and long-term survival in culture with no
signs of toxicity. In fact, over a 3-day period there was 25%
less cell death in cultured human islets incubated with KU-32
compared to those exposed to vehicle. It was interesting that
the KU-32-induced decrease in cell death was due to fewer
apoptotic cells, while there was no change in the amount of
necrotic core cell death with KU-32 exposure.
Glucose-stimulated insulin secretion was increased in
human islets exposed to KU-32 for 24 hours, when measured
with static incubation or perifusion methods. It is important
to note in both situations that KU-32 had no effect on
insulin secretion in low-glucose concentration. Clinically, if
the compound induced an increase in insulin under low-
glucose conditions, any animal or person exposed to that
drug would be at risk for hypoglycemic events, as glucose-
sensitive insulin secretion is key to normal regulation of
blood glucose levels.
Interestingly, the in vitro effects of KU-32 did not appear
to use the same cellular mechanism in islets as neurons.
In rodent nerves, KU-32 increased Hsp70, and this protein
was necessary for the neuroprotective efficacy of the drug
in reversing indices of diabetic peripheral neuropathy [4].
In contrast to the rodent neurons, KU-32 did not induce
an increase in Hsp70 in isolated cadaveric human islets.
However, it has been shown that human islets express
significantly higher levels of Hsp70 than rodents even under
quiescent conditions, and human islets have a dramatically















































Figure 6: Lepr db mice had islets that were categorized into three types. (a) Immunofluorescence (left) and immunohistochemistry (right)
illustrate the 3 types of islets that were identified in the Lepr db mice. Upper panels show intact islets, middle panels include disrupted islets,
and lower panels show scattered islet cells. (b) There was no statistical difference in the distribution of the islet categories between the vehicle-
and KU-32-treated mice pancreata (n = 12–16 sections from each of 3 mice/group).
smaller dynamic response to heat and stress compared
to rodent Hsp70 levels [22, 23]. Our results support this
conclusion, as Hsp70 levels in rat muscle (used in the western
blots as a positive control) were nearly 1000 times less than
human islets levels (data not shown). New data suggest that
other molecular mechanisms may be activated in response
to KU-32, such as mortalin/Grp75, Hsp60 and antioxidant
proteins such as Mn superoxide dismutase [13]. Thus, the

















































































Figure 7: KU-32 improved the total islet area, but not the islet density or cell composition. (a) Treatment with KU-32 increased the total
area of the pancreas identified by immunohistochemistry as endocrine cells. (∗indicates P < 0.007, n = 40 islet from vehicle-treated mice,
and 46 islets from KU-32 treated mice). (b) KU-32 decreased the density of islets per pancreatic section analyzed. (∗indicates P < 0.05, n =
analysis of 4 sections from 3 vehicle-treated mice and 6 sections from 3 KU-32-treated mice). (c) There was no difference in the percentage
of α, β, or δ cells in each islet analyzed. (n = 56 islets from vehicle-treated mice and 40 islets from KU-32 treated mice).
lack of increase in Hsp70 levels in human islets in our study
should not be surprising.
In vivo KU-32 did not reverse the blood glucose levels of
severely diabetic mice. This may have been because the islet
integrity was too diminished before the administration of
KU-32 was initiated. While KU-32 did not spare islets from
the degradation associated with diabetes, it did maintain a
statistically higher level of insulin per β-cell. It would be
interesting to determine whether a greater effect of KU-32
could be measured, if the administration of the compound
was initiated earlier in the disease process. In fact, at the
initiation of KU-32 administration in this study, the blood
glucose levels were approximately 450 mg/dL, and it is likely
that the mice were already hyperinsulinemic, although we
did not measure blood insulin levels. Future studies will
examine the in vivo effect of KU-32 when administered
earlier in the course of the disease.
5. Conclusions
KU-32 is a small molecule designed to reverse diabetic
peripheral neuropathy, which it does effectively in rodent
models of diabetes. In cadaveric human islets, it enhanced in
vitro insulin secretion and improved islet viability in culture.
Yet, it did not improve glucose control in the db/db mice
at the time point tested. Certainly, KU-32 has been shown
in this study to be nontoxic to human islets at clinically
relevant doses and may be beneficial to islet health in vitro.
The in vitro implications of this compound should not
be overlooked. Laboratories have worked feverishly to add
molecules to islet media that would enhance their in vitro
survival, both for research purposes and as they prepare
and ship islets for transplantation into people with diabetes.
KU-32, or related analogs [24], may prove to be a useful
compound towards this goal as well as effectively treating
diabetic neuropathy.


































Figure 8: Insulin staining intensity per cell was higher with KU-32 treatment. Representative examples are shown of insulin
immunohistochemistry for islets from vehicle-treated and KU-32 administered mice. (b) Insulin staining intensity values (brown) were
background-subtracted (blue) and calculated as pixel intensity. KU-32 induced a significant increase in insulin staining. (∗indicates
P < 0.001, n = 313 β cells from 7 vehicle-treated mice and 682 β cells from 5 KU-32-treated mice).
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mic reticulum stress contributes to beta cell apoptosis in type
2 diabetes,” Diabetologia, vol. 50, no. 4, pp. 752–763, 2007.
[9] K. Bellmann, A. Wenz, J. Radons, V. Burkart, R. Kleemann,
and H. Kolb, “Heat shock induces resistance in rat pancreatic
islet cells against nitric oxide, oxygen radicals and streptozo-
tocin toxicity in vitro,” Journal of Clinical Investigation, vol. 95,
no. 6, pp. 2840–2845, 1995.
[10] D. Brandhorst, H. P. Hammes, H. Brandhorst et al., “Pretrans-
plant induction of HSP-70 in isolated adult pig islets decreases
Experimental Diabetes Research 11
early islet xenograft survival,” Cell Transplantation, vol. 9, no.
3, pp. 423–430, 2000.
[11] D. Brandhorst, H. Brandhorst, V. Kumarasamy et al., “Hyper-
thermic preconditioning protects pig islet grafts from early
inflammation but enhances rejection in immunocompetent
mice,” Cell Transplantation, vol. 12, no. 8, pp. 859–865, 2004.
[12] M. Urban, P. Pan, K. Farmer, H. Zhao, B. Blagg, and
R. Dobrowsky, “Modulating molecular chaperones improves
sensory fiber recovery and mitochondrial function in diabetic
peripheral neuropathy,” Experimental Neurology, vol. 235, no.
1, pp. 388–396, 2012.
[13] L. Zhang, H. Zhao, B. Blagg, and R. Dobrowsky, “C-terminal
heat shock protein 90 inhibitor decreases hyperglycemia-
induced oxidative stress and improves mitochondrial bioen-
ergetics in sensory neurons,” Journal of Proteome Research, vol.
4, no. 11, pp. 2581–2593, 2012.
[14] A. M. Vincent, J. L. Edwards, L. L. McLean et al., “Mitochon-
drial biogenesis and fission in axons in cell culture and animal
models of diabetic neuropathy,” Acta Neuropathologica, vol.
120, no. 4, pp. 477–489, 2010.
[15] Y. T. Huang and B. S. J. Blagg, “A library of noviosylated
coumarin analogues,” Journal of Organic Chemistry, vol. 72,
no. 10, pp. 3609–3613, 2007.
[16] R. R. MacGregor, S. J. Williams, P. Y. Tong, K. Kover, W. V.
Moore, and L. Stehno-Bittel, “Small rat islets are superior
to large islets in in vitro function and in transplantation
outcomes,” American Journal of Physiology, vol. 290, no. 5, pp.
E771–E779, 2006.
[17] S. Williams, T. Schwasinger-Schmidt, D. Zamierowski, and
L. Stehno-Bittel, “Diffusion into human islets is limited to
molecules below 10kDa,” Tissue Cell, vol. 44, pp. 332–341,
2012.
[18] S. J. Williams, H. H. Huang, K. Kover et al., “Reduction of dif-
fusion barriers in isolated rat islets improves survival, but not
insulin secretion or transplantation outcome,” Organogenesis,
vol. 6, no. 2, pp. 115–124, 2010.
[19] M. Giuliani, W. Moritz, E. Bodmer et al., “Central necrosis
in isolated hypoxic human pancreatic islets: evidence for
postisolation ischemia,” Cell Transplantation, vol. 14, no. 1, pp.
67–76, 2005.
[20] Z. Su, J. Xia, W. Shao et al., “Small islets are essential for
successful intraportal transplantation in a diabetes mouse
model,” Scandinavian Journal of Immunology, vol. 72, no. 6,
pp. 504–510, 2010.
[21] J. Henriksnas, J. Lau, G. Zang, P. Berggren, M. Kohler, and P.
Carlsson, “Markedly decreased blood perfusion of pancreatic
islets transplanted intraportally into the liver: disruption of
islet integrity necessary for islet revascularization,” Diabetes,
vol. 61, pp. 665–673, 2012.
[22] N. Welsh, B. Margulis, L. A. Borg et al., “Differences in the
expression of heat-shock proteins and antioxidant enzymes
between human and rodent pancreatic islets: implications
for the pathogenesis of insulin-dependent diabetes mellitus,”
Molecular Medicine, vol. 1, no. 7, pp. 806–820, 1995.
[23] S. Rodrı́guez-Mulero and E. Montanya, “Islet graft response
to transplantation injury includes upregulation of protective
as well as apoptotic genes,” Cell Transplantation, vol. 17, no. 9,
pp. 1025–1034, 2008.
[24] B. Kusuma, A. Duerfeldt, and B. Blagg, “Synthesis and
biological evaluation of arylated novobiocin analogs as Hsp90
inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 21,
pp. 7170–7174, 2011.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
